EUVIMEDEUVIMED entdecken
Crossref

TMOD3 accelerated resistance to immunotherapy in KRAS-mutated pancreatic cancer through promoting autophagy-dependent degradation of ASCL4

Zhiwei He, Dijie Zheng, Futang Li, Liwen Chen, Changhao Wu, Zhirui Zeng, Chao Yu

Drug Resistance Updates · 2025-01 · 78 · 101171

DOI: 10.1016/j.drup.2024.101171 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Resistance Updates, 2025-01. Verfasst von Zhiwei He und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, The Affiliated Hospital of Guizhou Medical University, Guizhou Medical University, Guiyang 550001, China; School…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Autophagy, Proto-Oncogene Proteins p21(ras), Drug Resistance, Neoplasm. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Guizhou Medical University, Science and Technology Program of Guizhou Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The high prevalence of KRAS mutations in pancreatic cancer (PC) is widely acknowledged and results in the resistance of targeted ferroptosis therapy and immunotherapy. Herein, via a CRISPR/Cas9 library screen, the effects of ferroptosis agonists were increased in KRAS-mutant PC cells upon knockout of tropomodulin 3 (TMOD3), while these effects were not observed in KRAS-wild-type cells. Increased levels of TMOD3 were found in PC tissues, particularly in those with KRAS mutations. The increase in TMOD3 expression was facilitated by KRAS via the ETS transcription factor ELK1. Liquid chromatography-mass spectrometry (LC/MS) showed that TMOD3 increased acyl-CoA synthetase long chain family member 4 (ACSL4) protein expression and fatty acid metabolism. Mechanistically, TMOD3 promoted F-actin polymerization, thereby facilitating the fusion of autophagosomes with lysosomes, increasing the degradation of the ACSL4 protein, and augmenting the ferroptosis-inducing effects of RSL3. These effects of TMOD3 were counteracted by the administration of cytochalasin, the removal of the α2 domain of TMOD3, or the introduction of a mutation at S71. Cangrelor, an FDA-approved drug, can target TMOD3. In a mouse model, the suppression of TMOD3 using cangrelor or gene silencing technology resulted in increased infiltration of CD8+ T cells into tumor tissues with KRAS mutations and exhibited a synergistic effect with the PD-1 antibody. In conclusion, TMOD3 was found to inhibit ferroptosis and induced the resistance to PD-1 antibody by facilitating the fusion of autophagosomes and lysosomes through the promotion of F-actin polymerization in KRAS-mutant PC. TMOD3 was identified as a novel target for PC therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsAutophagyProto-Oncogene Proteins p21(ras)Drug Resistance, NeoplasmFerroptosisMutationAnimalsHumansMiceImmunotherapyCell Line, Tumor

Stichwörter der Autor:innen

F-actin polymerizationFerroptosisKRAS mutationPancreatic cancerTMOD3

Substanzen

Proto-Oncogene Proteins p21(ras)KRAS protein, human

Autor:innen und Institutionen

  • Department of Hepatobiliary Surgery, The Affiliated Hospital of Guizhou Medical University, Guizhou Medical University, Guiyang 550001, China; School of Clinical Medicine, Guizhou Medical University, Guiyang, China; Gui…
  • Department of Hepatobiliary Surgery, The Affiliated Hospital of Guizhou Medical University, Guizhou Medical University, Guiyang 550001, China; College of Basic Medicine, Guizhou Medical University, Guiyang 550001, China…
  • College of Basic Medicine, Guizhou Medical University, Guiyang 550001, China; Transformation Engineering Research Center of Chronic Disease Diagnosis and Treatment, Department of Physiology, College of Basic Medicine, G…

Förderung

  • National Natural Science Foundation of China
  • Guizhou Medical University
  • Science and Technology Program of Guizhou Province

Zitieren

APA

He, Z., Zheng, D., Li, F., Chen, L., Wu, C., Zeng, Z., & Yu, C. (2025). TMOD3 accelerated resistance to immunotherapy in KRAS-mutated pancreatic cancer through promoting autophagy-dependent degradation of ASCL4. Drug Resistance Updates, 78, 101171. https://doi.org/10.1016/j.drup.2024.101171

Vancouver

He Z, Zheng D, Li F, Chen L, Wu C, Zeng Z, et al. TMOD3 accelerated resistance to immunotherapy in KRAS-mutated pancreatic cancer through promoting autophagy-dependent degradation of ASCL4. Drug Resistance Updates. 2025;78:101171. doi:10.1016/j.drup.2024.101171

BibTeX
@article{He2025,
  author = {He, Zhiwei and Zheng, Dijie and Li, Futang and Chen, Liwen and Wu, Changhao and Zeng, Zhirui and Yu, Chao},
  title = {TMOD3 accelerated resistance to immunotherapy in KRAS-mutated pancreatic cancer through promoting autophagy-dependent degradation of ASCL4},
  journal = {Drug Resistance Updates},
  year = {2025},
  volume = {78},
  pages = {101171},
  doi = {10.1016/j.drup.2024.101171}
}
Kostenlos starten →